Stories from the dialysis comunity across the globe.
|
Kallikrein inhibitor ecallantide shows some benefit in ACEI-associated angioedema. |
|
|
University of Cincinnati: They wanted to see if Ecallantide, which has already safely treated acute attacks of hereditary angioedema, could help patients with ACEI angioedema—specifically, if it could make them eligible for discharge within four hours of treatment. After enrolling 50 patients in the study, they found that patients treated with Ecallantide were more likely to meet discharge sooner than those receiving antihistamines and steroids—31 percent of Ecallantide patients were eligible for discharge within four hours, as compared with 21 percent of patients receiving placebos. Additionally, patients experienced few side effects from the medication.
|
|
|
|
<< Start < Prev 401 402 403 404 405 406 407 408 409 410 Next > End >>
|
Page 410 of 4210 |